ClinicalTrials.gg
Not yet recruitingNCT07942545DATES-ACUpdated Nov 17, 2026

Duration of Antibiotic Therapy Evaluation Study in Acute Cholangitis (DATES-AC): An Open-Label, Multicenter, Randomized Non-Inferiority Trial Comparing Short-Course Versus Standard-Course Antibiotic Therapy After ERCP With Early Intravenous-to-oral Switch in Patients With Acute Cholangitis

An interventional study of duration of antibiotics in Cholangitis Acute, sponsored by Seoul National University Hospital. Not yet recruiting at 5 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Seoul National University Hospital · Not applicable, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
330
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

Acute cholangitis is an infection of the bile ducts, usually caused by a blockage that prevents bile from flowing normally. It can lead to serious complications if not treated promptly. Treatment generally includes antibiotics and drainage of the blocked bile duct, usually through a procedure called endoscopic retrograde cholangiopancreatography (ERCP).

Although antibiotics are essential for treating acute cholangitis, the optimal duration of antibiotic treatment after successful bile duct drainage remains uncertain. Current guidelines generally recommend 4 to 7 days of antibiotic treatment. However, shorter treatment may be sufficient after the source of infection has been effectively controlled, potentially reducing unnecessary antibiotic exposure, side effects, hospital stay, and healthcare costs.

The purpose of this study is to determine whether a shorter course of antibiotic treatment (4 days) is as effective as the standard course (7 days) in patients with moderate to severe acute cholangitis who have undergone successful bile duct drainage.

This is a multicenter, randomized, open-label study involving adults aged 19 years or older with moderate to severe acute cholangitis. Patients whose bile duct obstruction has been successfully relieved by ERCP within one day of hospital admission and who meet the study eligibility criteria may participate. Eligible patients will be randomly assigned in a 1:1 ratio to one of two treatment groups.

The short-course group will receive antibiotics for a total of 4 days, while the standard-course group will receive antibiotics for a total of 7 days. In both groups, intravenous antibiotics will initially be given for at least 2 days. Patients who are clinically stable and able to take oral medication will be switched to oral antibiotics as early as possible. Antibiotic selection may be adjusted according to bacterial culture results and antibiotic susceptibility testing. If the initial antibiotics are found to be ineffective, or if the patient's clinical condition requires additional treatment, the antibiotics may be changed or extended to ensure patient safety.

The primary outcome is the clinical cure rate within 14 days after randomization. Cure will be assessed based on the resolution of infection-related symptoms and improvement in blood bilirubin levels, defined as a reduction of at least 50% from the initial level or normalization, without predefined treatment failure events.

Secondary outcomes include recurrence of cholangitis between days 14 and 30 among patients who initially achieve clinical cure, all-cause mortality within 30 days, total duration of antibiotic use, and patient-reported health status and satisfaction with treatment. The incidence of adverse events within 14 days will also be evaluated. Additional assessments will compare hospital stay and total treatment costs between the two groups.

Participants will be followed up at approximately 14 and 30 days after randomization to assess treatment outcomes, recurrence of infection, additional antibiotic use, and safety.

This study aims to provide evidence on whether a 4-day antibiotic treatment strategy, combined with early conversion from intravenous to oral antibiotics after successful bile duct drainage, can achieve comparable treatment outcomes to the standard 7-day regimen. The findings may help establish a more appropriate antibiotic treatment strategy for patients with acute cholangitis while reducing unnecessary antibiotic exposure and its associated burden.

Read the detailed description
  • 1. Empirical IV Antibiotics Ceftriaxone + Metronidazole
  • 2. Culture-directed IV Antibiotics Ciprofloxacin Piperacillin/Tazobactam Ertapenem Meropenem
  • 3. PO Antibiotics Cefpodoxime proxetil Amoxicillin/Clavulanate
02

Conditions studied

  • Cholangitis Acute

Browse trials for

Keywords

  • cholangitis, acute
  • antibiotics
  • biliary drainage
  • endoscopic retrograde biliary drainage
03

In context

Cholangitis

83 studies on the registry are indexed under Cholangitis; 18 are open to participants now.

This study's planned enrollment of 330 is above the median of 100 across 53 interventional studies indexed under Cholangitis.

Browse Cholangitis studies →

Lead sponsor

Seoul National University Hospital is the lead sponsor of 1,902 studies on the registry; 276 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 19 years or older.
  • Patients who voluntarily agree to participate in the study and provide written after receiving a full explanation of the study.
  • Patients who meet the diagnostic criteria for suspected or definite acute cholangitis according to the Tokyo Guidelines 2018 (TG18), regardless of whether the underlying cause is benign or malignant.
  • Patients with moderate or severe acute cholangitis according to the TG18 severity grading criteria.
  • Patients who have undergone successful biliary drainage by endoscopic retrograde cholangiopancreatography (ERCP) within one calendar day of hospital admission, resulting in relief of biliary obstruction.

Exclusion criteria

Exclusion Criteria:

  • Circulatory failure requiring vasopressor support at the time of ERCP.
  • Persistent or newly developed hypothermia (body temperature below 35°C) between hospital admission and screening.
  • Patients requiring intensive care unit (ICU) treatment.
  • Use of antibiotics within 7 days before hospital admission.
  • Use of systemic antibiotics for 7 days or longer within 90 days before study enrollment for an infection unrelated to the current episode of acute cholangitis.
  • History of recurrent acute cholangitis within the previous 3 months.
  • Complex biliary strictures classified as Bismuth type II or higher.
  • Biliary obstruction of unknown cause.
  • Acute cholangitis caused by dysfunction of a distal biliary stent when the stent was inserted less than 30 days before study enrollment.
  • Complications associated with acute cholangitis present at the time of study enrollment, including acute cholecystitis, acute pancreatitis, liver abscess, or intra-abdominal abscess.
  • Presence of an infection other than acute cholangitis at the time of study enrollment.
  • Patients at high risk of infective endocarditis caused by Gram-positive bacteria, including those with prosthetic heart valves, congenital heart disease, or a previous history of infective endocarditis.
  • Complications following ERCP, including perforation, bleeding, severe post-ERCP pancreatitis, or cardiopulmonary complications related to sedation.
  • Altered upper gastrointestinal anatomy due to previous upper abdominal surgery, except for Billroth I gastrectomy.
  • patients, including:

    1. Patients receiving systemic at a dose equivalent to prednisolone 20 mg/day or higher for at least 14 consecutive days.
    2. Patients who have received cytotoxic chemotherapy, biological agents, or immunosuppressive therapy within the previous 3 months.
    3. Patients with hematologic or a history of hematopoietic stem cell transplantation.
    4. Patients who have undergone solid organ transplantation (liver, kidney, heart, lung, etc.) and are currently receiving immunosuppressive therapy.
    5. Patients with congenital or primary immunodeficiency disorders.
    6. Patients with advanced infection, defined as a CD4-positive T-cell count below 200 cells/μL.
  • Pregnant or breastfeeding women.
  • Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation in this study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
330 participants (estimated)

Study arms

  • Experimental
    a shorter course of antibiotic treatment

    4 days of antibiotics including PO antibioitcs

    Other: duration of antibiotics

  • Active comparator
    a standard course of antibiotic treatment

    7 days of antibiotics including PO antibioitcs

    Other: duration of antibiotics

Interventions

  • Otherduration of antibiotics

    Comparision of duration of antibiotics

06

What researchers measure

Primary outcomes

  1. the clinical cure rate within 14 days after randomization

    Cure will be assessed based on the resolution of infection-related symptoms and improvement in blood bilirubin levels, defined as a reduction of at least 50% from the initial level or normalization, without predefined treatment failure events.

    Time frame: Within 14 days after randomization (Day 14; assessment window: Day 11-Day 18)

Secondary outcomes

  1. Recurrence rate of acute cholangitis

    Recurrence of cholangitis after cure

    Time frame: From Day 14 to Day 30 after randomization

  2. All-cause mortality

    Death regardless of cause

    Time frame: Within 30 days after randomization

  3. Patient-reported health status (EQ-5D-5L)

    Patient self reports regarding health status

    Time frame: Day 2 and Day 14 after randomization

  4. Patient satisfaction with treatment (TSQM-II)

    Patient self reports regarding satisfaction with treatment

    Time frame: Day 14 after randomization

  5. Total duration of antibiotic use

    Days with antibiotics

    Time frame: Within 30 days after randomization

  6. DOOR/RADAR composite outcome

    Scoring system regarding the treatment outcomes

    Time frame: Day 30 after randomization

Other outcomes

  1. Hospital stays

    Duration of hospital stay

    Time frame: Within 30 days after randomization

  2. Total medical costs

    Total medical costs for the treatment

    Time frame: Within 30 days after randomization

07

Study locations

5 sites
08

References and documents

Publications

  • Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985 Apr-Jun;4(2):213-26. doi: 10.1002/sim.4780040211. PubMed 4023479 ↗
  • Pouwels KB, Yin M, Butler CC, Cooper BS, Wordsworth S, Walker AS, Robotham JV. Optimising trial designs to identify appropriate antibiotic treatment durations. BMC Med. 2019 Jun 21;17(1):115. doi: 10.1186/s12916-019-1348-z. PubMed 31221165 ↗
  • Evans SR, Rubin D, Follmann D, Pennello G, Huskins WC, Powers JH, Schoenfeld D, Chuang-Stein C, Cosgrove SE, Fowler VG Jr, Lautenbach E, Chambers HF. Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR). Clin Infect Dis. 2015 Sep 1;61(5):800-6. doi: 10.1093/cid/civ495. Epub 2015 Jun 25. PubMed 26113652 ↗
  • Masuda S, Imamura Y, Kimura K, Makazu M, Kubota J, Takihara H, Jinushi R, Fujikawa T, Maejima K, Kawanishi A, Yamamoto R, Noda S, Koyama T, Sugitani A, Ryozawa S, Koizumi K. Optimizing short-term antibiotic treatment in patients with acute cholangitis: study protocol for an open-label randomized controlled trial (the BOLT-P3 trial). Trials. 2025 Sep 1;26(1):324. doi: 10.1186/s13063-025-09077-1. PubMed 40890775 ↗
  • Lee TS, Choi JH, Lee JM, Jeon H, Paik WH, Cho KB, Lee YS, Han JH, Joo JS, Jung MK, Lee J, Ahn DW, Park JM, Kim J, Lee JC, Cho EA, Lee SH. A randomized non-inferiority trial investigating antibiotic adjustments based on blood culture in acute cholangitis. Clin Microbiol Infect. 2025 Jun;31(6):987-994. doi: 10.1016/j.cmi.2024.12.039. Epub 2025 Jan 27. PubMed 39880122 ↗
  • Srinu D, Shah J, Jena A, Jearth V, Singh AK, Mandavdhare HS, Sharma V, Irrinki S, Sakaray YR, Gupta R, Gautam V, Rana S, Dutta U. Conventional vs Short Duration of Antibiotics in Patients With Moderate or Severe Cholangitis: Noninferiority Randomized Trial. Am J Gastroenterol. 2024 Jan 1;119(1):176-182. doi: 10.14309/ajg.0000000000002499. Epub 2023 Sep 21. PubMed 37732816 ↗
  • Sawyer RG, Claridge JA, Nathens AB, Rotstein OD, Duane TM, Evans HL, Cook CH, O'Neill PJ, Mazuski JE, Askari R, Wilson MA, Napolitano LM, Namias N, Miller PR, Dellinger EP, Watson CM, Coimbra R, Dent DL, Lowry SF, Cocanour CS, West MA, Banton KL, Cheadle WG, Lipsett PA, Guidry CA, Popovsky K; STOP-IT Trial Investigators. Trial of short-course antimicrobial therapy for intraabdominal infection. N Engl J Med. 2015 May 21;372(21):1996-2005. doi: 10.1056/NEJMoa1411162. PubMed 25992746 ↗
  • Sartelli M, Barie P, Agnoletti V, Al-Hasan MN, Ansaloni L, Biffl W, Buonomo L, Blot S, Cheadle WG, Coimbra R, De Simone B, Duane TM, Fugazzola P, Giamarellou H, Hardcastle TC, Hecker A, Inaba K, Kirkpatrick AW, Labricciosa FM, Leone M, Martin-Loeches I, Maier RV, Marwah S, Maves RC, Mingoli A, Montravers P, Ordonez CA, Palmieri M, Podda M, Rello J, Sawyer RG, Sganga G, Tattevin P, Thapaliya D, Tessier J, Tolonen M, Ulrych J, Vallicelli C, Watkins RR, Catena F, Coccolini F. Intra-abdominal infections survival guide: a position statement by the Global Alliance For Infections In Surgery. World J Emerg Surg. 2024 Jun 8;19(1):22. doi: 10.1186/s13017-024-00552-9. PubMed 38851700 ↗
  • Mazuski JE, Tessier JM, May AK, Sawyer RG, Nadler EP, Rosengart MR, Chang PK, O'Neill PJ, Mollen KP, Huston JM, Diaz JJ Jr, Prince JM. The Surgical Infection Society Revised Guidelines on the Management of Intra-Abdominal Infection. Surg Infect (Larchmt). 2017 Jan;18(1):1-76. doi: 10.1089/sur.2016.261. PubMed 28085573 ↗
  • Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, O'Neill PJ, Chow AW, Dellinger EP, Eachempati SR, Gorbach S, Hilfiker M, May AK, Nathens AB, Sawyer RG, Bartlett JG. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010 Jan 15;50(2):133-64. doi: 10.1086/649554. PubMed 20034345 ↗
  • Gomi H, Solomkin JS, Schlossberg D, Okamoto K, Takada T, Strasberg SM, Ukai T, Endo I, Iwashita Y, Hibi T, Pitt HA, Matsunaga N, Takamori Y, Umezawa A, Asai K, Suzuki K, Han HS, Hwang TL, Mori Y, Yoon YS, Huang WS, Belli G, Dervenis C, Yokoe M, Kiriyama S, Itoi T, Jagannath P, Garden OJ, Miura F, de Santibanes E, Shikata S, Noguchi Y, Wada K, Honda G, Supe AN, Yoshida M, Mayumi T, Gouma DJ, Deziel DJ, Liau KH, Chen MF, Liu KH, Su CH, Chan ACW, Yoon DS, Choi IS, Jonas E, Chen XP, Fan ST, Ker CG, Gimenez ME, Kitano S, Inomata M, Mukai S, Higuchi R, Hirata K, Inui K, Sumiyama Y, Yamamoto M. Tokyo Guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis. J Hepatobiliary Pancreat Sci. 2018 Jan;25(1):3-16. doi: 10.1002/jhbp.518. Epub 2018 Jan 9. PubMed 29090866 ↗
  • Miura F, Okamoto K, Takada T, Strasberg SM, Asbun HJ, Pitt HA, Gomi H, Solomkin JS, Schlossberg D, Han HS, Kim MH, Hwang TL, Chen MF, Huang WS, Kiriyama S, Itoi T, Garden OJ, Liau KH, Horiguchi A, Liu KH, Su CH, Gouma DJ, Belli G, Dervenis C, Jagannath P, Chan ACW, Lau WY, Endo I, Suzuki K, Yoon YS, de Santibanes E, Gimenez ME, Jonas E, Singh H, Honda G, Asai K, Mori Y, Wada K, Higuchi R, Watanabe M, Rikiyama T, Sata N, Kano N, Umezawa A, Mukai S, Tokumura H, Hata J, Kozaka K, Iwashita Y, Hibi T, Yokoe M, Kimura T, Kitano S, Inomata M, Hirata K, Sumiyama Y, Inui K, Yamamoto M. Tokyo Guidelines 2018: initial management of acute biliary infection and flowchart for acute cholangitis. J Hepatobiliary Pancreat Sci. 2018 Jan;25(1):31-40. doi: 10.1002/jhbp.509. Epub 2018 Jan 8. PubMed 28941329 ↗
  • Kiriyama S, Kozaka K, Takada T, Strasberg SM, Pitt HA, Gabata T, Hata J, Liau KH, Miura F, Horiguchi A, Liu KH, Su CH, Wada K, Jagannath P, Itoi T, Gouma DJ, Mori Y, Mukai S, Gimenez ME, Huang WS, Kim MH, Okamoto K, Belli G, Dervenis C, Chan ACW, Lau WY, Endo I, Gomi H, Yoshida M, Mayumi T, Baron TH, de Santibanes E, Teoh AYB, Hwang TL, Ker CG, Chen MF, Han HS, Yoon YS, Choi IS, Yoon DS, Higuchi R, Kitano S, Inomata M, Deziel DJ, Jonas E, Hirata K, Sumiyama Y, Inui K, Yamamoto M. Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholangitis (with videos). J Hepatobiliary Pancreat Sci. 2018 Jan;25(1):17-30. doi: 10.1002/jhbp.512. Epub 2018 Jan 5. PubMed 29032610 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Dec 2029, 35 months later.

Of 21 interventional studies with no phase under Cholangitis, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 68. This study's planned 35 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 17, 2026
StartEst.
Jan 1, 2027
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2029
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07942545
Collaborators
Korean Government-wide R&D Fund for Infectious Disease Research (GFID)
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Nov 17, 2026

Study contacts

Jaihwan Kim, MD. PhD.
Contact
drjaihwan@snu.ac.kr
+82-31-787-7075
Kwangrok Jung, MD. PhD.
Contact
herojkr@snubh.org
Jaihwan Kim
principal investigator · Seoul National University Bundang Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion